Multicoin Capital has invested $1.75 million as the sole institutional backer in Trasia Labs, which launched a specialized perpetual futures trading platform built on Hyperliquid. The platform targets Asian markets with bilingual support and a mobile app planned for August, focusing on assets in high-interest sectors like AI and upcoming public listings. Trasia aims to attract new decentralized trading users through a mobile-first, localized approach, leveraging Hyperliquid’s infrastructure to deepen on-chain liquidity in regional equities. This investment signals confidence in Hyperliquid’s ecosystem growth and Trasia’s potential to expand decentralized finance tools in Asia.
Axsome Therapeutics received an "Outperform" rating from BMO Capital due to significant progress in its drug pipeline, including FDA acceptance of its NDA for AXS-12, a narcolepsy treatment with a PDUFA date set for May 1, 2027. The company is also a...
Novartis is set to report its Q2 earnings with analysts expecting an EPS of $2.17 and revenue of $14.07 billion, following a tough Q1 affected by major patent expirations. Despite revenue challenges, the company maintained strong cash flow of $3.30 b...
KeyCorp is set to report earnings with analysts forecasting a 20% increase in earnings per share to $0.42 and an 8% rise in total revenue to $1.97 billion. The growth is mainly driven by a 10% increase in net interest income, fueled by strong commerc...
Several biotech and manufacturing companies saw significant stock declines due to key corporate events. Vision Marine Technologies dropped nearly 24% after shifting its focus from boat manufacturing to a mining project, causing investor uncertainty. ...
Shares of Zhengye Biotechnology surged over 1047% to regain Nasdaq compliance after a minimum bid price warning. Advanced Biomed and Axe Compute also saw notable gains following a reverse stock split and Russell Microcap Index inclusion, respectively...
